Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim.
Arshad
Muhammad
M
Department of Medicine, New York Medical College, Valhalla, NY, USA.
Seiter
Karen
K
Bilaniuk
Jaroslaw
J
Qureshi
Anila
A
Patil
Asawari
A
Ramaswamy
Gita
G
Liu
Delong
D
D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D013161:Splenic Rupture / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000601:surgery; D014057:Tomography, X-Ray Computed
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim